🔴 Moderna is trading 6.5% down today after profit-taking following its cancer-vaccine rally

Moderna is trading 6.5% down at $148.52 as investors continue taking profits after its extraordinary cancer-vaccine-driven rally.

• Recent coverage links the pullback to profit-taking and valuation concerns after positive Phase 3 results for Moderna and Merck’s personalized melanoma vaccine.
• The decline is occurring despite biotechnology sector strength, suggesting company-specific post-rally selling is outweighing broader sector support.
• No new negative announcement, earnings update, regulatory action, or analyst move was identified for August 26, 2026.